2. Search Result
Search Result
Results for "

necroptotic

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Inhibitory Antibodies

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112292
    GW806742X
    Maximum Cited Publications
    23 Publications Verification

    		 Mixed Lineage Kinase VEGFR Others
    GW806742X, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X has activity against VEGFR2 (IC50=2 nM). GW806742X retards MLKL membrane translocation and inhibits necroptosis .
    GW806742X
  • HY-N6004
    (Rac)-Shikonin
    1 Publications Verification

    Shikalkin

    		 Others Cancer
    (Rac)-Shikonin (Shikonin) possesses anti-tumor activity. (Rac)-Shikonin (Shikonin) circumvents cancer agent resistance by induction of a necroptotic death .
    (Rac)-Shikonin
  • HY-122912
    ALDH1A inhibitor 673A
    2 Publications Verification

    ALDH1Ai 673A

    		 Aldehyde Dehydrogenase (ALDH) Mitochondrial Metabolism Necroptosis Cancer
    ALDH1A inhibitor 673A is an ALDH1A inhibitor with IC50s of 246 nM (ALDH1A1), 230 nM (ALDH1A2), 348 nM (ALDH1A3), respectively. ALDH1A inhibitor 673A has little or no inhibitory effect on other ALDH family members. ALDH1A inhibitor 673A induces necroptotic ovarian cancer stem-like cells (CSCs) death. ALDH1A inhibitor 673A induces DNA double stand breaks in cancer cells. ALDH1A inhibitor 673A can be used for the study of ovarian cancer .
    ALDH1A inhibitor 673A
  • HY-151369
    AV123

    		RIP kinase Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    AV123 (compound 12) is a non-cytotoxic RIPK1 inhibitor (IC50=12.12 µM). AV123 blocks the TNF-α-induced necroptotic (EC50=1.7 μM) but not the apoptotic cell death. AV123 can be used in the study of necrotic chronic conditions such as ischemia-reperfusion injury of the brain, heart and kidney, inflammatory diseases, neurodegenerative diseases and infectious diseases .
    AV123
  • HY-112292A
    GW806742X hydrochloride
    Maximum Cited Publications
    23 Publications Verification

    		 Mixed Lineage Kinase VEGFR Cancer
    GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2 (IC50=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis .
    GW806742X hydrochloride
  • HY-162424
    ZBP1/RIP3/MLKL activator 1

    		RIP kinase Mixed Lineage Kinase Necroptosis Cancer
    ZBP1/RIP3/MLKL activator 1 (compound 3a) is a synthetically derived quinoline compound. ZBP1/RIP3/MLKL Activator 1 induces DNA damage, enhances intracellular levels of reactive oxygen species (ROS), and triggers apoptosis via the caspase pathway. Furthermore, when apoptosis is inhibited, ZBP1/RIP3/MLKL Activator 1 promotes necroptotic cell death through the ZBP1-RIP3-MLKL pathway. ZBP1/RIP3/MLKL Activator 1 is utilized in oncological research, particularly in the selective targeting of cells with impaired apoptotic function .
    ZBP1/RIP3/MLKL activator 1
  • HY-P990258
    Anti-Mouse CLEC9A/CD370 Antibody (7H11)

    		Transmembrane Glycoprotein C-type Lectin-like Receptors (CTLRs) Inflammation/Immunology Cancer
    Anti-Mouse CLEC9A/CD370 Antibody (7H11) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse CLEC9A/CD370. Anti-Mouse CLEC9A/CD370 Antibody (7H11) reacts with mouse CLEC9A (C-type lectin domain family member 9A) and blocks CLEC9A. Anti-Mouse CLEC9A/CD370 Antibody (7H11) can be used for the researches of cancer and immunology, such as B16.F10-OVA tumor .
    Anti-Mouse CLEC9A/CD370 Antibody (7H11)
  • HY-178163
    Zharp1-163

    		Ferroptosis Necroptosis RIP kinase Reactive Oxygen Species (ROS) Mixed Lineage Kinase Inflammation/Immunology
    Zharp1-163 is a dual inhibitor of ferroptosis and necroptosis. Zharp1-163 effectively blocks ferroptosis by reducing reactive oxygen species (ROS) levels and inhibits necroptosis by potently and selectively targeting RIPK1 kinase activity (KD = 240 nM; IC50 = 406.1 nM). Zharp1-163 inhibits the cellular activation of RIPK1, RIPK3 and MLKL in response to necroptotic stimulation. Zharp1-163 markedly attenuates TNF-α (HY-P1875)-induced systemic inflammatory syndrome, including the prevention of TNF-α-induced mortality and hypothermia in mice. Zharp1-163 significantly alleviates acute kidney injury associated with both necroptosis and ferroptosis in models induced by Cisplatin (HY-17394) and ischemia-reperfusion. Zharp1-163 can be used for the study of diseases associated with cell death pathways, such as kidney disease .
    Zharp1-163
  • HY-146758
    RIPK1-IN-14

    		RIP kinase Neurological Disease Inflammation/Immunology
    RIPK1-IN-14 (Compound 41) is a potent inhibitor of RIPK1 with an IC50 value of 92 nM. RIPK1-IN-14 shows a significant anti-necroptotic effect in a necroptosis model in U937 cells .
    RIPK1-IN-14
  • HY-157963
    RIPK1-IN-23

    		RIP kinase Necroptosis Inflammation/Immunology Cancer
    RIPK1-IN-23 (compound 19) is a RIPK1 inhibitor with potent anti-necroptotic effects in HT-29 cells (EC50 of 1.7 nM). RIPK1-IN-23 shows anti-inflammatory activities .
    RIPK1-IN-23
  • HY-149052
    SZM-1209

    		RIP kinase Mixed Lineage Kinase Necroptosis Inflammation/Immunology
    SZM-1209 is an orally active, potent and specific RIPK1 inhibitor, with a Kd of 85 nM. SZM-1209 exhibits high anti-necroptotic activity (EC50=22.4 ± 8.1 nM). SZM-1209 shows anti-SIRS (systemic inflammatory response syndrome), and anti-ALI (acute lung injury) effects .
    SZM-1209
  • HY-170232
    RIPK1-IN-29

    		RIP kinase Inflammation/Immunology
    RIPK1-IN-29 (Compound 22) is a RIPK1 inhibitor, with an IC50 of 6.9 nM. RIPK1-IN-29 exerts anti-necroptotic (Apoptosis) activity by inhibiting RIPK1. In a TNF-α-induced in vivo inflammation model, at a dose of 10 mg/kg, RIPK1-IN-29 can protect mice from hypothermia and death. RIPK1-IN-29 can be applied to the research field of inflammatory diseases .
    RIPK1-IN-29
  • HY-181944
    RIPK1-IN-40

    		RIP kinase Necroptosis Cancer
    RIPK1-IN-40 (Compound 51) is a RIPK1 inhibitor and anti-necroptotic agent (with an EC50 of 0.07 μM against necroptosis). RIPK1-IN-40 binds to the kinase domain of RIPK1, forms hydrogen bond interactions with Met95, and establishes additional polar contacts with Asp156 to stabilize binding, thereby inhibiting necroptosis. RIPK1-IN-40 can be used for the research of colorectal cancer .
    RIPK1-IN-40
  • HY-179680
    RIPK1-IN-38

    		RIP kinase Necroptosis Mixed Lineage Kinase Lactate Dehydrogenase Interleukin Related Inflammation/Immunology
    RIPK1-IN-38 is an orally active RIPK1 inhibitor with an IC50 value of 27 nM. RIPK1-IN-38 can inhibit the phosphorylation of RIPK1 and its downstream signaling molecules RIPK3 and MLKL. RIPK1-IN-38 exhibits anti-necroptotic activity. RIPK1-IN-38 has excellent anti-inflammatory efficacy in both the SIRS model and GVHD model. RIPK1-IN-38 can be used for the research of inflammatory and immune-related diseases .
    RIPK1-IN-38
  • HY-185652
    dTAG-TRIMTAC

    		PROTACs E1/E2/E3 Enzyme Neurological Disease Inflammation/Immunology
    dTAG-TRIMTAC is a PROTAC-like degrader targeting TRIM21. dTAG-TRIMTAC forms a ternary complex with TRIM21 and target proteins to drive degradation of oligomeric/assembled substrates via TRIM21 clustering-based activation, with degradation dependent on endogenous TRIM21. dTAG-TRIMTAC can be used for the research of neurodegenerative disease and inflammatory disease .
    dTAG-TRIMTAC

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: